Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 871 Präparate · 48256 Quellenpassagen · 124 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Gegenanzeigen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.3 · PDF-Seite 4
HOS-086138 · Präparat HOS-083284
Concomitant medicinal product levels increased or decreased
1-Adrenoreceptor Alfuzosin Increased plasma concentrations of alfuzosin
Antagonist which may lead to severe hypotension (see
section 4.5).
Analgesics Pethidine, Increased plasma concentrations of
propoxyphene norpethidine and propoxyphene. Thereby,
increasing the risk of serious respiratory
depression or haematologic abnormalities, or
other serious adverse effects from these agents.
Antianginal Ranolazine Increased plasma concentrations of ranolazine
which may increase the potential for serious
and/or life-threatening reactions (see section
4.5).
Anticancer Neratinib Increased plasma concentrations of neratinib
which may increase the potential for serious
and/or life-threatening reactions including
hepatotoxicity (see section 4.5).
Venetoclax Increased plasma concentrations of venetoclax.
Increased risk of tumor lysis syndrome at the
dose initiation and during the dose-titration
phase (see section 4.5).
Antiarrhythmics Amiodarone, bepridil, Increased plasma concentrations of amiodarone,
dronedarone, bepridil, dronedarone, encainide, flecanide,
encainide, flecanide, propafenone, quinidine. Thereby, increasing the
propafenone, quinidine risk of arrhythmias or other serious adverse
reactions from these agents.
Antibiotic Fusidic Acid Increased plasma concentrations of fusidic acid
and ritonavir.
Anti-gout Colchicine Potential for serious and/or life-threatening
reactions in patients with renal and/or hepatic
impairment (see sections 4.4 and 4.5).
Antihistamines Astemizole, Increased plasma concentrations of astemizole
terfenadine and terfenadine. Thereby, increasing the risk of
serious arrhythmias from these agents.
Antipsychotics/ Lurasidone Increased plasma concentrations of lurasidone
Neuroleptics which may increase the potential for serious
and/or life-threatening reactions (see section
4.5).
Clozapine, pimozide Increased plasma concentrations of clozapine
and pimozide. Thereby, increasing the risk of
serious haematologic abnormalities, or other
serious adverse effects from these agents.
Quetiapine Increased plasma concentrations of quetiapine
which may lead to coma. The concomitant
administration with quetiapine is
contraindicated (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): encainide (HOS-086145) propafenone (HOS-084530) quinidine (HOS-085593) fusidic acid (HOS-086146) colchicine (HOS-086147) astemizole (HOS-085608) terfenadine (HOS-085607) lurasidone (HOS-086148) clozapine (HOS-086149) pimozide (HOS-085600) quetiapine (HOS-086150) bepridil (HOS-085612) dronedarone (HOS-086144) alfuzosin (HOS-086139) lead (HOS-085592) propoxyphene (HOS-086140) ranolazine (HOS-086141) neratinib (HOS-086142) venetoclax (HOS-086143) amiodarone (HOS-085596)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage f9fe97979894eedcce9660008265f9fc818cdb3984974bb2555b6c5e5869e4e5 · Zeichen 902–5292 im Abschnitt
Gegenanzeigen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 35–36
HOS-086388 · Präparat HOS-083284
35
Analgesics Pethidine, Increased plasma concentrations of
propoxyphene norpethidine and propoxyphene. Thereby,
increasing the risk of serious respiratory
depression or haematologic abnormalities, or
other serious adverse effects from these agents.
Antianginal Ranolazine Increased plasma concentrations of ranolazine
which may increase the potential for serious
and/or life-threatening reactions (see section
4.5).
Anticancer Neratinib Increased plasma concentrations of neratinib
which may increase the potential for serious
and/or life-threatening reactions including
hepatotoxicity (see section 4.5).
Venetoclax Increased plasma concentrations of venetoclax.
Increased risk of tumor lysis syndrome at the
dose initiation and during the dose-titration
phase (see section 4.5).
Antiarrhythmics Amiodarone, bepridil, Increased plasma concentrations of amiodarone,
dronedarone, bepridil, dronedarone, encainide, flecainide,
encainide, flecainide, propafenone, quinidine. Thereby, increasing
propafenone, quinidine the risk of arrhythmias or other serious adverse
effects from these agents.
Antibiotic Fusidic Acid Increased plasma concentrations of fusidic acid
and ritonavir.
Antihistamines Astemizole, Increased plasma concentrations of astemizole
terfenadine and terfenadine. Thereby, increasing the risk of
serious arrhythmias from these agents.
Anti-gout Colchicine Potential for serious and/or life-threatening
reactions in patients with renal and/or hepatic
impairment (see sections 4.4 and 4.5).
Antipsychotics/ Lurasidone Increased plasma concentrations of lurasidone
Neuroleptics which may increase the potential for serious
and/or life-threatening reactions (see section
4.5).
Clozapine, pimozide Increased plasma concentrations of clozapine
and pimozide. Thereby, increasing the risk of
serious haematologic abnormalities, or other
serious adverse effects from these agents.
Quetiapine Increased plasma concentrations of quetiapine
which may lead to coma. The concomitant
administration with quetiapine is
contraindicated (see section 4.5).
Ergot Derivatives Dihydroergotamine, Increased plasma concentrations of ergot
ergonovine, derivatives leading to acute ergot toxicity,
ergotamine, including vasospasm and ischaemia.
methylergonovine
GI motility agent Cisapride Increased plasma concentrations of cisapride.
Thereby, increasing the risk of serious
arrhythmias from this agent.
Lipid-modifying agents
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lead (HOS-085592) dihydroergotamine (HOS-086152) ergonovine (HOS-086153) ergotamine (HOS-086154) methylergonovine (HOS-086155) cisapride (HOS-085610) quinidine (HOS-085593) fusidic acid (HOS-086146) astemizole (HOS-085608) terfenadine (HOS-085607) colchicine (HOS-086147) lurasidone (HOS-086148) clozapine (HOS-086149) pimozide (HOS-085600) quetiapine (HOS-086150) propoxyphene (HOS-086140) ranolazine (HOS-086141) neratinib (HOS-086142) venetoclax (HOS-086143) amiodarone (HOS-085596) bepridil (HOS-085612) dronedarone (HOS-086144) encainide (HOS-086145) flecainide (HOS-086203) propafenone (HOS-084530)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage f76b82bf2af9e33f5778d35af3ff4a8ea2ea8d392666af7950204db67ec4ac88 · Zeichen 1234–5743 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 18
HOS-086282 · Präparat HOS-083284
Lurasidone Due to CYP3A inhibition by ritonavir, concentrations of lurasidone are expected to
increase. The concomitant administration with lurasidone is contraindicated (see
section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lurasidone (HOS-086148)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 0b2cddd70a9d0e6e84f198bdfb2c2d8fddadfcdf329efa4d0cb73db5d20d076e · Zeichen 38292–38592 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 51
HOS-086460 · Präparat HOS-083284
Lurasidone Due to CYP3A inhibition by ritonavir, concentrations of lurasidone are expected to
increase. The concomitant administration with lurasidone is contraindicated (see section
4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lurasidone (HOS-086148)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 9a901670059096c3f491f539bb11730c25bd259aea37f3ebe13a675f7bc6cec8 · Zeichen 40083–40383 im Abschnitt
Gegenanzeigen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.3 · PDF-Seite 5
HOS-108791 · Präparat HOS-093083
Concomitant medicinal product levels increased
Alpha1-adrenoreceptor Alfuzosin Increased plasma concentrations of
antagonist alfuzosin which may lead to severe
hypotension. The concomitant
administration with alfuzosin is
contraindicated (see section 4.5).
Antianginal Ranolazine Increased plasma concentrations of
ranolazine which may increase the
potential for serious and/or life-
threatening reactions (see section 4.5).
Antiarrhythmics Amiodarone, dronedarone Increased plasma concentrations of
amiodarone and dronedarone. Thereby,
increasing the risk of arrhythmias or
other serious adverse reactions (see
section 4.5).
Antibiotic Fusidic Acid Increased plasma concentrations of
fusidic acid. The concomitant
administration with fusidic acid is
contraindicated in dermatological
infections (see section 4.5).
Anticancer Neratinib Increased plasma concentrations of
neratinib which may increase the
potential for serious and/or
life-threatening reactions (see section
4.5).
Venetoclax Increased plasma concentrations of
venetoclax. Increased risk of tumor lysis
syndrome at the dose initiation and
during the ramp-up phase (see section
4.5).
Anti-gout Colchicine Increased plasma concentrations of
colchicine. Potential for serious and/or
life-threatening reactions in patients with
renal and/or hepatic impairment (see
sections 4.4 and 4.5).
Antihistamines Astemizole, terfenadine Increased plasma concentrations of
astemizole and terfenadine. Thereby,
increasing the risk of serious
arrhythmias from these agents (see
section 4.5).
Antipsychotics/ Lurasidone Increased plasma concentrations of
Neuroleptics lurasidone which may increase the
potential for serious and/or life-
threatening reactions (see section 4.5).
Pimozide Increased plasma concentrations of
pimozide. Thereby, increasing the risk
of serious haematologic abnormalities,
or other serious adverse effects from this
agent (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dronedarone (HOS-086144) fusidic acid (HOS-086146) neratinib (HOS-086142) venetoclax (HOS-086143) colchicine (HOS-086147) astemizole (HOS-085608) terfenadine (HOS-085607) lurasidone (HOS-086148) pimozide (HOS-085600) alfuzosin (HOS-086139) lead (HOS-085592) ranolazine (HOS-086141) amiodarone (HOS-085596)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 3af5f7da19ec49492414676af6b40d10b1389f87518dc00840ff964623d97870 · Zeichen 617–4755 im Abschnitt
Gegenanzeigen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 42–43
HOS-108988 · Präparat HOS-093083
42
Antihistamines Astemizole, terfenadine Increased plasma concentrations of
astemizole and terfenadine. Thereby,
increasing the risk of serious
arrhythmias from these agents (see
section 4.5).
Antipsychotics/ Lurasidone Increased plasma concentrations of
Neuroleptics lurasidone which may increase the
potential for serious and/or life-
threatening reactions (see section 4.5).
Pimozide Increased plasma concentrations of
pimozide. Thereby, increasing the risk
of serious haematologic abnormalities,
or other serious adverse effects from
this agent (see section 4.5).
Quetiapine Increased plasma concentrations of
quetiapine which may lead to coma.
The concomitant administration with
quetiapine is contraindicated (see
section 4.5).
Ergot alkaloids Dihydroergotamine, ergonovine, Increased plasma concentrations of
ergotamine, methylergonovine ergot derivatives leading to acute ergot
toxicity, including vasospasm and
ischaemia (see section 4.5).
GI motility agent Cisapride Increased plasma concentrations of
cisapride. Thereby, increasing the risk
of serious arrhythmias from this agent
(see section 4.5).
Hepatitis C virus Elbasvir/grazoprevir Increased risk of alanine transaminase
direct acting antivirals (ALT) elevations (see section 4.5).
Lipid-modifying agents
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): hepatitis C virus (HOS-108813) elbasvir (HOS-108814) grazoprevir (HOS-108815) alanine (HOS-088949) astemizole (HOS-085608) terfenadine (HOS-085607) lurasidone (HOS-086148) pimozide (HOS-085600) quetiapine (HOS-086150) lead (HOS-085592) ergot alkaloids (HOS-108807) dihydroergotamine (HOS-086152) ergonovine (HOS-086153) ergotamine (HOS-086154) methylergonovine (HOS-086155) cisapride (HOS-085610)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 513868d9cbc220f8b16283ba405e7ae3a7eba9be191b93bb320faa5cdf17028c · Zeichen 3976–6635 im Abschnitt
Gegenanzeigen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 77–78
HOS-109062 · Präparat HOS-093083
77
Venetoclax Increased plasma concentrations of
venetoclax. Increased risk of tumor lysis
syndrome at the dose initiation and during
the ramp-up phase (see section 4.5).
Anti-gout Colchicine Increased plasma concentrations of
colchicine. Potential for serious and/or
life-threatening reactions in patients with
renal and/or hepatic impairment (see
sections 4.4 and 4.5).
Antihistamines Astemizole, terfenadine Increased plasma concentrations of
astemizole and terfenadine. Thereby,
increasing the risk of serious arrhythmias
from these agents (see section 4.5).
Antipsychotics/ Lurasidone Increased plasma concentrations of
Neuroleptics lurasidone which may increase the
potential for serious and/or life-
threatening reactions (see section 4.5).
Pimozide Increased plasma concentrations of
pimozide. Thereby, increasing the risk of
serious haematologic abnormalities, or
other serious adverse effects from this
agent (see section 4.5).
Quetiapine Increased plasma concentrations of
quetiapine which may lead to coma. The
concomitant administration with
quetiapine is contraindicated (see section
4.5).
Ergot alkaloids Dihydroergotamine, ergonovine, Increased plasma concentrations of ergot
ergotamine, methylergonovine derivatives leading to acute ergot toxicity,
including vasospasm and ischaemia (see
section 4.5).
GI motility agent Cisapride Increased plasma concentrations of
cisapride. Thereby, increasing the risk of
serious arrhythmias from this agent (see
section 4.5).
Hepatitis C virus direct Elbasvir/grazoprevir Increased risk of alanine transaminase
acting antivirals (ALT) elevations (see section 4.5).
Lipid-modifying agents
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methylergonovine (HOS-086155) cisapride (HOS-085610) hepatitis C virus (HOS-108813) elbasvir (HOS-108814) grazoprevir (HOS-108815) alanine (HOS-088949) venetoclax (HOS-086143) colchicine (HOS-086147) astemizole (HOS-085608) terfenadine (HOS-085607) lurasidone (HOS-086148) pimozide (HOS-085600) quetiapine (HOS-086150) lead (HOS-085592) ergot alkaloids (HOS-108807) dihydroergotamine (HOS-086152) ergonovine (HOS-086153) ergotamine (HOS-086154)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage deedafd686f2a7856b9535fd14424479a75da74b88007e447ddb2a759abcc3fe · Zeichen 2941–6504 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 19–20
HOS-108904 · Präparat HOS-093083
19
Rifampicin Lopinavir: Co-administration of Kaletra with
Large decreases in lopinavir rifampicin is not recommended as
concentrations may be observed the decrease in lopinavir
due to CYP3A induction by concentrations may in turn
rifampicin. significantly decrease the lopinavir
therapeutic effect. A dose
adjustment of Kaletra
400 mg/400 mg (i.e. Kaletra
400/100 mg + ritonavir 300 mg)
twice daily has allowed
compensating for the CYP 3A4
inducer effect of rifampicin.
However, such a dose adjustment
might be associated with ALT/AST
elevations and with increase in
gastrointestinal disorders.
Therefore, this co-administration
should be avoided unless judged
strictly necessary. If this
co-administration is judged
unavoidable, increased dose of
Kaletra at 400 mg/400 mg twice
daily may be administered with
rifampicin under close safety and
therapeutic drug monitoring. The
Kaletra dose should be titrated
upward only after rifampicin has
been initiated (see section 4.4).
Antipsychotics
Lurasidone Due to CYP3A inhibition by The concomitant administration
lopinavir/ritonavir, with lurasidone is contraindicated
concentrations of lurasidone are (see section 4.3).
expected to increase.
Pimozide Due to CYP3A inhibition by Concomitant administration of
lopinavir/ritonavir, Kaletra and pimozide is
concentrations of pimozide are contraindicated as it may increase
expected to increase. the risk of serious haematologic
abnormalities or other serious
adverse effects from this agent (see
section 4.3)
Quetiapine Due to CYP3A inhibition by Concomitant administration of
lopinavir/ritonavir, Kaletra and quetiapine is
concentrations of quetiapine are contraindicated as it may increase
expected to increase. quetiapine-related toxicity.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lurasidone (HOS-086148) pimozide (HOS-085600) quetiapine (HOS-086150)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 0cd97f605d9ff9f95bd037eca67e54d94e990128412fa438a0aa4c28977553c1 · Zeichen 38367–41870 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 55–56
HOS-109015 · Präparat HOS-093083
55
Rifampicin Lopinavir: Co-administration of Kaletra with
Large decreases in lopinavir rifampicin is not recommended as
concentrations may be observed the decrease in lopinavir
due to CYP3A induction by concentrations may in turn
rifampicin. significantly decrease the lopinavir
therapeutic effect. A dose adjustment
of Kaletra 400 mg/400 mg (i.e.
Kaletra 400/100 mg + ritonavir
300 mg) twice daily has allowed
compensating for the CYP 3A4
inducer effect of rifampicin.
However, such a dose adjustment
might be associated with ALT/AST
elevations and with increase in
gastrointestinal disorders. Therefore,
this co-administration should be
avoided unless judged strictly
necessary. If this co-administration is
judged unavoidable, increased dose
of Kaletra at 400 mg/400 mg twice
daily may be administered with
rifampicin under close safety and
therapeutic drug monitoring. The
Kaletra dose should be titrated
upward only after rifampicin has been
initiated (see section 4.4).
Antipsychotics
Lurasidone Due to CYP3A inhibition by The concomitant administration with
lopinavir/ritonavir, concentrations lurasidone is contraindicated (see
of lurasidone are expected to section 4.3).
increase.
Pimozide Due to CYP3A inhibition by Concomitant administration of
lopinavir/ritonavir, concentrations Kaletra and pimozide is
of pimozide are expected to contraindicated as it may increase the
increase. risk of serious haematologic
abnormalities or other serious
adverse effects from this agent (see
section 4.3)
Quetiapine Due to CYP3A inhibition by Concomitant administration of
lopinavir/ritonavir, concentrations Kaletra and quetiapine is
of quetiapine are expected to contraindicated as it may increase
increase. quetiapine-related toxicity.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lurasidone (HOS-086148) pimozide (HOS-085600) quetiapine (HOS-086150)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage c8939a16b64f6d8ec4a19ded0cb5af8a6d3c243259de96cb30a89f8088ddcbc4 · Zeichen 37143–40650 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 90–91
HOS-109091 · Präparat HOS-093083
90
Rifabutin, 150 mg QD Rifabutin (parent drug and active When given with Kaletra the
25-O-desacetyl metabolite): recommended dose of rifabutin is
AUC: ↑ 5.7-fold 150 mg 3 times per week on set
Cmax: ↑ 3.5-fold days (for example Monday-
Wednesday-Friday). Increased
monitoring for rifabutin-associated
adverse reactions including
neutropenia and uveitis is warranted
due to an expected increase in
exposure to rifabutin. Further
dosage reduction of rifabutin to
150 mg twice weekly on set days is
recommended for patients in whom
the 150 mg dose 3 times per week is
not tolerated. It should be kept in
mind that the twice weekly dosage
of 150 mg may not provide an
optimal exposure to rifabutin thus
leading to a risk of rifamycin
resistance and a treatment failure.
No dose adjustment is needed for
Kaletra.
Rifampicin Lopinavir: Co-administration of Kaletra with
Large decreases in lopinavir rifampicin is not recommended as
concentrations may be observed the decrease in lopinavir
due to CYP3A induction by concentrations may in turn
rifampicin. significantly decrease the lopinavir
therapeutic effect. A dose
adjustment of Kaletra
400 mg/400 mg (i.e. Kaletra
400/100 mg + ritonavir 300 mg)
twice daily has allowed
compensating for the CYP 3A4
inducer effect of rifampicin.
However, such a dose adjustment
might be associated with ALT/AST
elevations and with increase in
gastrointestinal disorders.
Therefore, this co-administration
should be avoided unless judged
strictly necessary. If this
co-administration is judged
unavoidable, increased dose of
Kaletra at 400 mg/400 mg twice
daily may be administered with
rifampicin under close safety and
therapeutic drug monitoring. The
Kaletra dose should be titrated
upward only after rifampicin has
been initiated (see section 4.4).
Antipsychotics
Lurasidone Due to CYP3A inhibition by The concomitant administration
lopinavir/ritonavir, concentrations with lurasidone is contraindicated
of lurasidone are expected to (see section 4.3).
increase.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifabutin (HOS-086262) lurasidone (HOS-086148)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage ef631cb168a202ad49cd1e5d830eb707073235478031c2a079706957841b1d31 · Zeichen 35398–40311 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 14–15
HOS-112085 · Präparat HOS-093615
14
Medicinal products by Interaction Recommendations concerning co-
therapeutic area administration
ANTIMYCOBACTERIAL
Rifabutin 150 mg twice weekly Rifabutin AUC: ↑48% (↑19% ↑84%)** When given with REYATAZ, the
(atazanavir 300 mg and ritonavir Rifabutin Cmax: ↑149% (↑103% ↑206%)** recommended dose of rifabutin is
100 mg once daily) Rifabutin Cmin: ↑40% (↑5% ↑87%)** 150 mg 3 times per week on set
days (for example Monday-
25-O-desacetyl-rifabutin AUC: ↑990% Wednesday-Friday). Increased
(↑714% ↑1 361%)** monitoring for rifabutin-associated
25-O-desacetyl-rifabutin Cmax: ↑677% adverse reactions including
(↑513% ↑883%)** neutropenia and uveitis is warranted
25-O-desacetyl-rifabutin Cmin: ↑1 045% due to an expected increase in
(↑715% ↑1 510%)** exposure to rifabutin. Further
dosage reduction of rifabutin to
**When compared to rifabutin 150 mg 150 mg twice weekly on set days is
once daily alone. Total rifabutin and recommended for patients in whom
25-O-desacetyl-rifabutin AUC: ↑119% the 150 mg dose 3 times per week
(↑78% ↑169%). is not tolerated. It should be kept in
mind that the twice weekly dosage
In previous studies, the pharmacokinetics of 150 mg may not provide an
of atazanavir was not altered by rifabutin. optimal exposure to rifabutin thus
leading to a risk of rifamycin
resistance and a treatment failure.
No dose adjustment is needed for
REYATAZ.
Rifampicin Rifampicin is a strong CYP3A4 inducer The combination of rifampicin and
and has been shown to cause a 72% REYATAZ is contraindicated
decrease in atazanavir AUC which can (see section 4.3).
result in virological failure and resistance
development. During attempts to
overcome the decreased exposure by
increasing the dose of REYATAZ or other
protease inhibitors with ritonavir, a high
frequency of liver reactions was seen.
ANTIPSYCHOTICS
Quetiapine Due to CYP3A4 inhibition by REYATAZ, Co-administration of quetiapine
concentrations of quetiapine are expected with REYATAZ is contraindicated
to increase. as REYATAZ may increase
quetiapine-related toxicity.
Increased plasma concentrations of
quetiapine may lead to coma
(see section 4.3).
Lurasidone REYATAZ is expected to increase plasma Co-administration of lurasidone
levels of lurasidone due to CYP3A4 with REYATAZ is contraindicated
inhibition. as this may increase lurasidone-
related toxicity (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lurasidone (HOS-086148) rifabutin (HOS-086262) ritonavir (HOS-084521) protease (HOS-085623) quetiapine (HOS-086150) lead (HOS-085592)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 57ec8478d6e13f3ffb31841798fe0270300e604091177c3b0241de94938bc9c0 · Zeichen 26684–31429 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 44
HOS-112157 · Präparat HOS-093615
Atazanavir is metabolised in the liver through CYP3A4. It inhibits CYP3A4. Therefore, REYATAZ
with ritonavir is contraindicated with medicinal products that are substrates of CYP3A4 and have a
narrow therapeutic index: quetiapine, lurasidone, alfuzosin, astemizole, terfenadine, cisapride,
pimozide, quinidine, bepridil, triazolam, orally administered midazolam, lomitapide, and ergot
alkaloids, particularly ergotamine and dihydroergotamine (see section 4.3). Co-administration of
REYATAZ with grazoprevir-containing products, including elbasvir/grazoprevir fixed-dose
combination is contraindicated because of the increase in grazoprevir and elbasvir plasma
concentrations and potential for the increase in risk of ALT elevations associated with increased
grazoprevir concentrations (see section 4.3). Co-administration of REYATAZ with
glecaprevir/pibrentasvir fixed-dose combination is contraindicated because of the potential increase in
the risk of ALT elevations due to a significant increase in glecapreir and pibrentasvir plasma
concentrations (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bepridil (HOS-085612) triazolam (HOS-086168) midazolam (HOS-086167) lomitapide (HOS-086160) ergotamine (HOS-086154) dihydroergotamine (HOS-086152) elbasvir (HOS-108814) grazoprevir (HOS-108815) glecaprevir (HOS-086297) pibrentasvir (HOS-086298) ritonavir (HOS-084521) quetiapine (HOS-086150) lurasidone (HOS-086148) alfuzosin (HOS-086139) astemizole (HOS-085608) terfenadine (HOS-085607) cisapride (HOS-085610) pimozide (HOS-085600) quinidine (HOS-085593)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 8c472f02d161fbf877b321685a02acd6721db094612098433562a9a244834b35 · Zeichen 315–1385 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 50–51
HOS-112181 · Präparat HOS-093615
50
Medicinal products by Interaction Recommendations
therapeutic area concerning co-administration
Rifampicin Rifampicin is a strong CYP3A4 inducer The combination of rifampicin
and has been shown to cause a 72% and REYATAZ is
decrease in atazanavir AUC which can contraindicated (see
result in virological failure and resistance section 4.3).
development. During attempts to overcome
the decreased exposure by increasing the
dose of REYATAZ or other protease
inhibitors with ritonavir, a high frequency
of liver reactions was seen.
ANTIPSYCHOTICS
Quetiapine Due to CYP3A4 inhibition by REYATAZ, Co-administration of
concentrations of quetiapine are expected quetiapine with REYATAZ is
to increase. contraindicated as REYATAZ
may increase quetiapine-
related toxicity. Increased
plasma concentrations of
quetiapine may lead to coma
(see section 4.3).
Lurasidone REYATAZ is expected to increase plasma Co-administration of
levels of lurasidone due to CYP3A4 lurasidone with REYATAZ is
inhibition. contraindicated as this may
increase lurasidone-related
toxicity (see section 4.3).
ACID REDUCING AGENTS
H2-Receptor antagonists
Without Tenofovir
In HIV-infected patients with atazanavir/ritonavir at the recommended For patients not taking
dose 300/100 mg once daily tenofovir, if REYATAZ
Famotidine 20 mg twice daily Atazanavir AUC: ↓18% (↓25% ↑1%) 300 mg/ritonavir 100 mg and
Atazanavir Cmax: ↓20% (↓32% ↓7%) H2-receptor antagonists are co-
Atazanavir Cmin: ↔1% (↓16% ↑18%) administered, a dose equivalent
to famotidine 20 mg twice
Famotidine 40 mg twice daily Atazanavir AUC: ↓23% (↓32% ↓14%) daily should not be exceeded.
Atazanavir Cmax: ↓23% (↓33% ↓12%) If a higher dose of an H2-
Atazanavir Cmin: ↓20% (↓31% ↓8%) receptor antagonist is required
In healthy volunteers with atazanavir/ritonavir at an increased dose (e.g., famotidine 40 mg twice
of 400/100 mg once daily daily or equivalent) an increase
Famotidine 40 mg twice daily Atazanavir AUC: ↔3% (↓14% ↑22%) of the REYATAZ/ritonavir
Atazanavir Cmax: ↔2% (↓13% ↑8%) dose from 300/100 mg to
Atazanavir Cmin: ↓14% (↓32% ↑8%) 400/100 mg can be considered.
With Tenofovir disoproxil fumarate 300 mg once daily (equivalent to 245 mg tenofovir disoproxil)
In HIV-infected patients with atazanavir/ritonavir at the recommended dose For patients who are taking
of 300/100 mg once daily tenofovir disoproxil
Famotidine 20 mg twice daily Atazanavir AUC: ↓21% (↓34% ↓4%)* fumarate, if
Atazanavir Cmax: ↓21% (↓36% ↓4%)* REYATAZ/ritonavir with both
Atazanavir Cmin: ↓19% (↓37% ↑5%)* tenofovir disoproxil fumarate
and an H2-receptor antagonist
Famotidine 40 mg twice daily Atazanavir AUC: ↓24% (↓36% ↓11%)* are co-administered, a dose
Atazanavir Cmax: ↓23% (↓36% ↓8%)* increase of REYATAZ to
Atazanavir Cmin: ↓25% (↓47% ↑7%)* 400 mg with 100 mg of
In HIV-infected patients with atazanavir/ritonavir at an increased dose ritonavir is recommended. A
of 400/100 mg once daily dose equivalent to famotidine
Famotidine 20 mg twice daily Atazanavir AUC: ↑18% (↑6.5% ↑30%)* 40 mg twice daily should not
Atazanavir Cmax: ↑18% (↑6.7% ↑31%)* be exceeded.
Atazanavir Cmin: ↑24% (↑10% ↑39%)*
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) protease (HOS-085623) ritonavir (HOS-084521) quetiapine (HOS-086150) lead (HOS-085592) lurasidone (HOS-086148) famotidine (HOS-112087) tenofovir disoproxil fumarate (HOS-110471) tenofovir disoproxil (HOS-108843) fumarate (HOS-108845)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage d69eeb45d796d1cd8f98e48958156005dc8ba777a37e1a215ebb755a767192dc · Zeichen 30340–35663 im Abschnitt
Gegenanzeigen · Aptivus
Aptivus 250 mg soft capsules · Abschnitt 4.3 · PDF-Seite 4
HOS-114797 · Präparat HOS-094169
Co-administration of Aptivus with low dose ritonavir, with active substances that are highly dependent
on CYP3A for clearance, and for which elevated plasma concentrations are associated with serious
and/or life-threatening events. These active substances include antiarrhythmics (such as amiodarone,
bepridil, quinidine), antihistamines (such as astemizole, terfenadine), ergot derivatives (such as
dihydroergotamine, ergonovine, ergotamine, methylergonovine), gastrointestinal motility agents (such
as cisapride), antipsychotics (such as pimozide, sertindole, quetiapine, lurasidone), sedatives/hypnotics
(such as orally administered midazolam and triazolam) and HMG-CoA reductase inhibitors (such as
simvastatin and lovastatin) (see section 4.5). Also the use of the alpha-1 adrenoceptor antagonist
alfuzosin, and sildenafil when used for the treatment of pulmonary arterial hypertension. In addition,
co-administration of Aptivus with low dose ritonavir, and medicinal products that are highly
dependent on CYP2D6 for clearance, such as the antiarrhythmics flecainide, propafenone and
metoprolol given in heart failure (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): quetiapine (HOS-086150) lurasidone (HOS-086148) midazolam (HOS-086167) triazolam (HOS-086168) simvastatin (HOS-086158) lovastatin (HOS-086157) alfuzosin (HOS-086139) sildenafil (HOS-086162) flecainide (HOS-086203) propafenone (HOS-084530) metoprolol (HOS-090094) pimozide (HOS-085600) sertindole (HOS-085601) ritonavir (HOS-084521) amiodarone (HOS-085596) bepridil (HOS-085612) quinidine (HOS-085593) astemizole (HOS-085608) terfenadine (HOS-085607) dihydroergotamine (HOS-086152) ergonovine (HOS-086153) ergotamine (HOS-086154) methylergonovine (HOS-086155) cisapride (HOS-085610)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T09:35:00Z · SHA-256 1c396190f98e89933229f2261b0e436bd43dac9c1de8e2dacaa36a755dc06dce · Passage 899ebcf3829943bae5ad39416161803c04f5d7f21f78b5a86a8cc0fb492896e8 · Zeichen 519–1660 im Abschnitt
Wechselwirkungen · Aptivus
Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 20–21
HOS-114846 · Präparat HOS-094169
20
Antipsychotics
Pimozide Based on theoretical The concomitant use of Aptivus,
Sertindole considerations, tipranavir, co- co-administered with low dose
Quetiapine administered with low dose ritonavir, with antipsychotics
Lurasidone ritonavir, is expected to increase such as pimozide, sertindole,
No interaction study pimozide, sertindole, quetiapine quetiapine or lurasidone is
performed and lurasidone concentrations. contraindicated due to potential
serious and/or life threatening
Inhibition of CYP 3A4 by events, including coma (see
tipranavir/r section 4.3)
Sedatives/hypnotics
Midazolam 2 mg QD (iv) First-dose tipranavir/r: Concomitant use of Aptivus, co-
Midazolam Cmax ↔ administered with low dose
Midazolam AUC ↑ 5.1 fold ritonavir, and sedative/hypnotics
such as oral midazolam is contra-
Steady-state tipranavir/r: indicated (see section 4.3). If
Midazolam Cmax ↓ 13% Aptivus with ritonavir is
Midazolam AUC ↑ 181% administered with parenteral
midazolam, close clinical
Midazolam 5 mg QD (po) First-dose tipranavir/r monitoring for respiratory
Midazolam Cmax ↑ 5.0 fold depression and/or prolonged
Midazolam AUC ↑ 27 fold sedation should be instituted and
dosage adjustment should be
Steady-state tipranavir/r considered.
Midazolam Cmax ↑ 3.7 fold
Midazolam AUC ↑ 9.8 fold
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): pimozide (HOS-085600) sertindole (HOS-085601) quetiapine (HOS-086150) ritonavir (HOS-084521) lurasidone (HOS-086148) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T09:35:00Z · SHA-256 1c396190f98e89933229f2261b0e436bd43dac9c1de8e2dacaa36a755dc06dce · Passage c0ae36602a84de2f358261153f971ebc4b7d808de8e77b14a53412046fd6d54e · Zeichen 52998–55199 im Abschnitt
Gegenanzeigen · Prezista
PREZISTA 100 mg/ml oral suspension · Abschnitt 4.3 · PDF-Seite 6
HOS-116288 · Präparat HOS-094447
Darunavir boosted with either ritonavir or cobicistat inhibits the elimination of active substances that
are highly dependent on CYP3A for clearance, which results in increased exposure to the
co-administered medicinal product. Therefore, concomitant treatment with such medicinal products
for which elevated plasma concentrations are associated with serious and/or life-threatening events is
contraindicated (applies to darunavir boosted with either ritonavir or cobicistat). These active
substances include e.g.:
- alfuzosin
- amiodarone, bepridil, dronedarone, ivabradine, quinidine, ranolazine
- astemizole, terfenadine
- colchicine when used in patients with renal and/or hepatic impairment (see section 4.5)
- ergot derivatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergonovine)
- elbasvir/grazoprevir
- cisapride
- dapoxetine
- domperidone
- naloxegol
- lurasidone, pimozide, quetiapine, sertindole (see section 4.5)
- triazolam, midazolam administered orally (for caution on parenterally administered midazolam,
see section 4.5)
- sildenafil - when used for the treatment of pulmonary arterial hypertension, avanafil
- simvastatin, lovastatin, lomitapide (see section 4.5)
- ticagrelor (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ranolazine (HOS-086141) astemizole (HOS-085608) terfenadine (HOS-085607) colchicine (HOS-086147) dihydroergotamine (HOS-086152) ergotamine (HOS-086154) methylergonovine (HOS-086155) elbasvir (HOS-108814) grazoprevir (HOS-108815) cisapride (HOS-085610) domperidone (HOS-114656) naloxegol (HOS-109428) lurasidone (HOS-086148) pimozide (HOS-085600) quetiapine (HOS-086150) sertindole (HOS-085601) triazolam (HOS-086168) midazolam (HOS-086167) sildenafil (HOS-086162) avanafil (HOS-086161) simvastatin (HOS-086158) lovastatin (HOS-086157) lomitapide (HOS-086160) ticagrelor (HOS-112065) ritonavir (HOS-084521) cobicistat (HOS-088111) alfuzosin (HOS-086139) amiodarone (HOS-085596) bepridil (HOS-085612) dronedarone (HOS-086144) ivabradine (HOS-109426) quinidine (HOS-085593)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage e2536d703754b5f39bebb9603c70a8d8759f7198e0666cec1af181c80f42d82c · Zeichen 1442–2753 im Abschnitt
Gegenanzeigen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 49
HOS-116497 · Präparat HOS-094447
Co-administration of PREZISTA with low dose ritonavir, with active substances that are highly
dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with
serious and/or life-threatening events. These active substances include e.g.:
- alfuzosin
- amiodarone, bepridil, dronedarone, ivabradine, quinidine, ranolazine
- astemizole, terfenadine
- colchicine when used in patients with renal and/or hepatic impairment (see section 4.5)
- ergot derivatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergonovine)
- elbasvir/grazoprevir
- cisapride
- dapoxetine
- domperidone
- naloxegol
- lurasidone, pimozide, quetiapine, sertindole (see section 4.5)
- triazolam, midazolam administered orally (for caution on parenterally administered midazolam,
see section 4.5)
- sildenafil - when used for the treatment of pulmonary arterial hypertension, avanafil
- simvastatin, lovastatin and lomitapide (see section 4.5)
- ticagrelor (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): astemizole (HOS-085608) terfenadine (HOS-085607) colchicine (HOS-086147) dihydroergotamine (HOS-086152) ergotamine (HOS-086154) methylergonovine (HOS-086155) elbasvir (HOS-108814) quinidine (HOS-085593) ranolazine (HOS-086141) ritonavir (HOS-084521) alfuzosin (HOS-086139) amiodarone (HOS-085596) bepridil (HOS-085612) dronedarone (HOS-086144) ivabradine (HOS-109426) grazoprevir (HOS-108815) cisapride (HOS-085610) domperidone (HOS-114656) naloxegol (HOS-109428) lurasidone (HOS-086148) pimozide (HOS-085600) quetiapine (HOS-086150) sertindole (HOS-085601) triazolam (HOS-086168) midazolam (HOS-086167) sildenafil (HOS-086162) avanafil (HOS-086161) simvastatin (HOS-086158) lovastatin (HOS-086157) lomitapide (HOS-086160) ticagrelor (HOS-112065)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 6a604bfa742092630f592a37246ad3ddd261ae7ceba904108fadd195ca4e43c8 · Zeichen 481–1534 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 19–20
HOS-116394 · Präparat HOS-094447
19
ANTIPSYCHOTICS/NEUROLEPTICS
Quetiapine Not studied. Boosted PREZISTA is Concomitant administration of
expected to increase these antipsychotic boosted PREZISTA and quetiapine
plasma concentrations. is contraindicated as it may
(CYP3A inhibition) increase quetiapine-related
toxicity. Increased concentrations
of quetiapine may lead to coma
(see section 4.3).
Perphenazine Not studied. Boosted PREZISTA is A dose decrease may be needed for
Risperidone expected to increase these antipsychotic these drugs when co-administered
Thioridazine plasma concentrations. with boosted PREZISTA.
(CYP3A, CYP2D6 and/or P-gp
Lurasidone inhibition) Concomitant administration of
Pimozide boosted PREZISTA and
Sertindole lurasidone, pimozide or sertindole
is contraindicated (see section 4.3).
β-BLOCKERS
Carvedilol Not studied. Boosted PREZISTA is Clinical monitoring is
Metoprolol expected to increase these β-blocker recommended when
Timolol plasma concentrations. co-administering boosted
(CYP2D6 inhibition) PREZISTA with β-blockers. A
lower dose of the β-blocker should
be considered.
CALCIUM CHANNEL BLOCKERS
Amlodipine Not studied. Boosted PREZISTA can be Clinical monitoring of therapeutic
Diltiazem expected to increase the plasma and adverse effects is
Felodipine concentrations of calcium channel recommended when these
Nicardipine blockers. medicines are concomitantly
Nifedipine (CYP3A and/or CYP2D6 inhibition) administered with boosted
Verapamil PREZISTA.
CORTICOSTEROIDS
Corticosteroids primarily Fluticasone: in a clinical study where Concomitant use of boosted
metabolised by CYP3A ritonavir 100 mg capsules twice daily PREZISTA and corticosteroids (all
(including were co-administered with 50 g routes of administration) that are
betamethasone, intranasal fluticasone propionate (4 times metabolised by CYP3A may
budesonide, fluticasone, daily) for 7 days in healthy subjects, increase the risk of development of
mometasone, prednisone, fluticasone propionate plasma systemic corticosteroid effects,
triamcinolone) concentrations increased significantly, including Cushing’s syndrome and
whereas the intrinsic cortisol levels adrenal suppression.
decreased by approximately 86% (90%
CI 82-89%). Greater effects may be Co-administration with CYP3A-
expected when fluticasone is inhaled. metabolised corticosteroids is not
Systemic corticosteroid effects including recommended unless the potential
Cushing’s syndrome and adrenal benefit to the patient outweighs the
suppression have been reported in risk, in which case patients should
patients receiving ritonavir and inhaled or be monitored for systemic
intranasally administered fluticasone. The corticosteroid effects.
effects of high fluticasone systemic
exposure on ritonavir plasma levels are Alternative corticosteroids which
unknown. are less dependent on CYP3A
metabolism e.g. beclomethasone
Other corticosteroids: interaction not should be considered, particularly
studied. Plasma concentrations of these for long term use.
medicinal products may be increased
when co-administered with boosted
PREZISTA, resulting in reduced serum
cortisol concentrations.
Dexamethasone Not studied. Dexamethasone may Systemic dexamethasone should
(systemic) decrease plasma concentrations of be used with caution when
darunavir. combined with boosted
(CYP3A induction) PREZISTA.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): felodipine (HOS-108908) quetiapine (HOS-086150) lead (HOS-085592) perphenazine (HOS-116395) risperidone (HOS-086280) thioridazine (HOS-086281) lurasidone (HOS-086148) pimozide (HOS-085600) sertindole (HOS-085601) carvedilol (HOS-115322) metoprolol (HOS-090094) timolol (HOS-090571) calcium (HOS-085615) amlodipine (HOS-086287) diltiazem (HOS-086288) nicardipine (HOS-090619) nifedipine (HOS-086289) verapamil (HOS-090602) fluticasone (HOS-108914) ritonavir (HOS-084521) betamethasone (HOS-090066) fluticasone propionate (HOS-086331) budesonide (HOS-086332) mometasone (HOS-114048) prednisone (HOS-084526) triamcinolone (HOS-086333) beclomethasone (HOS-086334) dexamethasone (HOS-084535)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 06bb26e6737c57cc3c74485aceb2076b3feb5ff5bad566ac99081f05e0924029 · Zeichen 52002–57572 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 61–62
HOS-116527 · Präparat HOS-094447
61
Perphenazine Not studied. PREZISTA is expected to A dose decrease may be needed for
Risperidone increase these antipsychotic plasma these drugs when co-administered
Thioridazine concentrations. with PREZISTA co-administered
(CYP3A, CYP2D6 and/or P-gp with low dose ritonavir.
inhibition)
Lurasidone Concomitant administration of
Pimozide PREZISTA with low dose
Sertindole ritonavir and lurasidone, pimozide
or sertindole is contraindicated
(see section 4.3).
β-BLOCKERS
Carvedilol Not studied. PREZISTA is expected to Clinical monitoring is
Metoprolol increase these β-blocker plasma recommended when
Timolol concentrations. co-administering PREZISTA with
(CYP2D6 inhibition) β-blockers. A lower dose of the
β-blocker should be considered.
CALCIUM CHANNEL BLOCKERS
Amlodipine Not studied. PREZISTA co-administered Clinical monitoring of therapeutic
Diltiazem with low dose ritonavir can be expected and adverse effects is
Felodipine to increase the plasma concentrations of recommended when these
Nicardipine calcium channel blockers. medicines are concomitantly
Nifedipine (CYP3A and/or CYP2D6 inhibition) administered with PREZISTA with
Verapamil low dose ritonavir.
CORTICOSTEROIDS
Corticosteroids primarily Fluticasone: in a clinical study where Concomitant use of PREZISTA
metabolised by CYP3A ritonavir 100 mg capsules twice daily with low dose ritonavir and
(including were co-administered with 50 g corticosteroids (all routes of
betamethasone, intranasal fluticasone propionate (4 times administration) that are
budesonide, fluticasone, daily) for 7 days in healthy subjects, metabolised by CYP3A may
mometasone, prednisone, fluticasone propionate plasma increase the risk of development of
triamcinolone) concentrations increased significantly, systemic corticosteroid effects,
whereas the intrinsic cortisol levels including Cushing’s syndrome and
decreased by approximately 86% (90% adrenal suppression.
CI 82-89%). Greater effects may be
expected when fluticasone is inhaled. Co-administration with CYP3A-
Systemic corticosteroid effects including metabolised corticosteroids is not
Cushing’s syndrome and adrenal recommended unless the potential
suppression have been reported in benefit to the patient outweighs the
patients receiving ritonavir and inhaled or risk, in which case patients should
intranasally administered fluticasone. The be monitored for systemic
effects of high fluticasone systemic corticosteroid effects.
exposure on ritonavir plasma levels are
unknown. Alternative corticosteroids which
are less dependent on CYP3A
Other corticosteroids: interaction not metabolism e.g. beclomethasone
studied. Plasma concentrations of these should be considered, particularly
medicinal products may be increased for long term use.
when co-administered with PREZISTA
with low dose ritonavir, resulting in
reduced serum cortisol concentrations.
Dexamethasone Not studied. Dexamethasone may Systemic dexamethasone should
(systemic) decrease plasma concentrations of be used with caution when
darunavir. combined with PREZISTA
(CYP3A induction) co-administered with low dose
ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): timolol (HOS-090571) calcium (HOS-085615) amlodipine (HOS-086287) diltiazem (HOS-086288) felodipine (HOS-108908) nicardipine (HOS-090619) nifedipine (HOS-086289) verapamil (HOS-090602) perphenazine (HOS-116395) risperidone (HOS-086280) thioridazine (HOS-086281) ritonavir (HOS-084521) lurasidone (HOS-086148) pimozide (HOS-085600) sertindole (HOS-085601) carvedilol (HOS-115322) metoprolol (HOS-090094) fluticasone (HOS-108914) betamethasone (HOS-090066) fluticasone propionate (HOS-086331) budesonide (HOS-086332) mometasone (HOS-114048) prednisone (HOS-084526) triamcinolone (HOS-086333) beclomethasone (HOS-086334) dexamethasone (HOS-084535)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 8b9ea54ec289adeef1a2f9f81165d44d84f0b8d5433cec6f77b7df8c89fd8286 · Zeichen 43290–48378 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 101–102
HOS-116617 · Präparat HOS-094447
101
ANTIPSYCHOTICS/NEUROLEPTICS
Quetiapine Not studied. Boosted PREZISTA is Concomitant administration of
expected to increase these antipsychotic boosted PREZISTA and quetiapine
plasma concentrations. is contraindicated as it may
(CYP3A inhibition) increase quetiapine-related
toxicity. Increased concentrations
of quetiapine may lead to coma
(see section 4.3).
Perphenazine Not studied. Boosted PREZISTA is A dose decrease may be needed for
Risperidone expected to increase these antipsychotic these drugs when co-administered
Thioridazine plasma concentrations. with boosted PREZISTA.
(CYP3A, CYP2D6 and/or P-gp
Lurasidone inhibition) Concomitant administration of
Pimozide boosted PREZISTA and
Sertindole lurasidone, pimozide or sertindole
is contraindicated (see section 4.3).
β-BLOCKERS
Carvedilol Not studied. Boosted PREZISTA is Clinical monitoring is
Metoprolol expected to increase these β-blocker recommended when
Timolol plasma concentrations. co-administering boosted
(CYP2D6 inhibition) PREZISTA with β-blockers. A
lower dose of the β-blocker should
be considered.
CALCIUM CHANNEL BLOCKERS
Amlodipine Not studied. Boosted PREZISTA can be Clinical monitoring of therapeutic
Diltiazem expected to increase the plasma and adverse effects is
Felodipine concentrations of calcium channel recommended when these
Nicardipine blockers. medicines are concomitantly
Nifedipine (CYP3A and/or CYP2D6 inhibition) administered with boosted
Verapamil PREZISTA.
CORTICOSTEROIDS
Corticosteroids primarily Fluticasone: in a clinical study where Concomitant use of boosted
metabolised by CYP3A ritonavir 100 mg capsules twice daily PREZISTA and corticosteroids (all
(including were co-administered with 50 g routes of administration) that are
betamethasone, intranasal fluticasone propionate (4 times metabolised by CYP3A may
budesonide, fluticasone, daily) for 7 days in healthy subjects, increase the risk of development of
mometasone, prednisone, fluticasone propionate plasma systemic corticosteroid effects,
triamcinolone) concentrations increased significantly, including Cushing’s syndrome and
whereas the intrinsic cortisol levels adrenal suppression.
decreased by approximately 86% (90%
CI 82-89%). Greater effects may be Co-administration with CYP3A-
expected when fluticasone is inhaled. metabolised corticosteroids is not
Systemic corticosteroid effects including recommended unless the potential
Cushing’s syndrome and adrenal benefit to the patient outweighs the
suppression have been reported in risk, in which case patients should
patients receiving ritonavir and inhaled or be monitored for systemic
intranasally administered fluticasone. The corticosteroid effects.
effects of high fluticasone systemic
exposure on ritonavir plasma levels are Alternative corticosteroids which
unknown. are less dependent on CYP3A
metabolism e.g. beclomethasone
Other corticosteroids: interaction not should be considered, particularly
studied. Plasma concentrations of these for long term use.
medicinal products may be increased
when co-administered with boosted
PREZISTA, resulting in reduced serum
cortisol concentrations.
Dexamethasone Not studied. Dexamethasone may Systemic dexamethasone should
(systemic) decrease plasma concentrations of be used with caution when
darunavir. combined with boosted
(CYP3A induction) PREZISTA.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): quetiapine (HOS-086150) lead (HOS-085592) perphenazine (HOS-116395) risperidone (HOS-086280) thioridazine (HOS-086281) lurasidone (HOS-086148) pimozide (HOS-085600) sertindole (HOS-085601) carvedilol (HOS-115322) metoprolol (HOS-090094) timolol (HOS-090571) calcium (HOS-085615) amlodipine (HOS-086287) diltiazem (HOS-086288) felodipine (HOS-108908) nicardipine (HOS-090619) nifedipine (HOS-086289) verapamil (HOS-090602) fluticasone (HOS-108914) ritonavir (HOS-084521) betamethasone (HOS-090066) fluticasone propionate (HOS-086331) budesonide (HOS-086332) mometasone (HOS-114048) prednisone (HOS-084526) triamcinolone (HOS-086333) beclomethasone (HOS-086334) dexamethasone (HOS-084535)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage ccb6e0bf9fbd4db134b19a5c68f5c32c6656fffa35e00c9b9b966f86c2226743 · Zeichen 51473–57044 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.